Week 26 Breakout Forecast: Short-Term Picks To Give You An Edge

Breakout Forecast Selections for Week 26:

Market conditions continue with medium volatility. The positive momentum gauge continues with another full week in yellow (medium) unchanged from a value of 44 at the end of the prior week. The all time low for the positive momentum selection gauge is 8 during week 14 and all time high is 120 during August 2017. Last published report: Week 25 Breakout Forecast

Total Return Chart: +79.82%

The Total Return Chart reflects total return of all stocks in the weekly portfolio.
My momentum gauge is based on the count of the momentum stocks screened as either positive accelerating and negative accelerating stocks based on my research algorithm. The combination of the two different types of momentum categories screened by my algorithm may help validate the quality of the overall market momentum strength. The negative momentum gauge is down slightly from 23 last week to 22 this week indicating low conditions of negative breakdowns.

Market fund flow update June 15 from ETF.com:

ETF flows were salvaged this week as the Russell reconstitution trade offset trade war concerns. On net, $7.5 billion flowed into U.S.-listed ETFs during the week ending Thursday, June 21, according to FactSet.

Heading into Thursday, ETFs were on track for net outflows of nearly $10 billion as traders eased up on their equity positions amid rising trade tensions between the U.S. and China. But then Thursday rolled around, and a whopping $16.5 billion flooded into ETFsmostly funds tracking Russell indices.

~ ETF.com

* Related to the extremely large influx of funds to Russell indices, I will be releasing the annual Russell 3000 anomaly selections based on the reconstitution that takes effect on Monday, 25 June, 2018.

This week I have selected 8 breakout stocks from the following sectors: 2 basic materials, 3 technology, 1 services, and 2 healthcare.

The new selections of positive momentum stocks for this week include:

ImmunoGen (IMGN) – Healthcare / Biotechnology Zion Oil & Gas (ZN) – Basic Materials / Independent Oil & Gas

These stocks are not necessarily recommended for long term buy/hold unless you are comfortable with very large price swings. As I continue to observe, strong momentum events usually last from one to three weeks and may encounter some substantial decline before returning again to positive gains.

These are the most volatile selections I offer from among all the different Value & Momentum portfolios. Proposed entry points for each of the selected stocks are as close to the highlighted prices in yellow on the charts at market open. All stocks are selected for high short-term breakout results over one to three weeks.

Breakout Stock Selections for Week 26

Note: all breakout stocks are selected based on my algorithm to increase the frequency of 10% gains within a short period of time. Price targets are estimated through an unrelated technical charting process for those who are looking for estimated exit points, however it is possible the momentum in these selections may move well beyond the initial target.

Pick #1: ImmunoGen (IMGN) – Healthcare / Biotechnology
Price Target: 14.00

Jun-22-18 07:30AM Free Technical Research on ImmunoGen and Three More Biotech EquitiesACCESSWIRE
Jun-21-18 08:15AM ImmunoGen Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jun-19-18 09:41AM ImmunoGen’s Lead Candidate Gets Fast Track for Ovarian Cancer Zacks
Jun-18-18 08:00AM ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer Business Wire

ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (NYSE:ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.

Most recent corporat presentation, June:


庐 (pembrolizumab) 庐 latin escalation cohort庐s a registered trademark of Clovis Rubraca 庐bevacizumab) expansion cohort -positive tumor types 伪 Patrntlcsolcnentantoniteadin over 50CLINICAL COLLABORATIONSymdariayubracawaitwCtoNisCN FORW A D I FORW ARD II     EXE HCIUMTERST ESTNROATMR GBICSPORIOARVTTY:NSINE
伪positive solid tumors ExpcoovbriaifashBrFRdNntrpli-noaatetriraasdcancer) Esahrioniniegap-aitonvarian cancer    CODMEPRERHOPNMGIREVETUXIMAB
edicine, f Centre, etwork CancerzaP ofe ancer oronto M. f nd ealth Amit argaret University University Ovarian Princess ergsagel Chair Daniel
selection reventive ProBphOylactic BRCfArstrategy pportunities?  unique tage nd A a es8 aligstag s;gnosis; at dvanced revent onrapy B) ancer t r ew arly nd challenges f evelopment,in disease sofmatesgynecologic ) iagnose creening y 008 . )wide V) susceptibility A) ethal  Fidea(thscan, Asymptomaticcall ffective Unique   No straBtegCies Most
OIvaiea eand Mortality 3
Rottapel cting ancer ith urrent nmet Niches ominant o Ovarian ith istinct eterogeneity Resistance o uttherapeuticallyease isease f Serous lonal preadem fensitivdriverilesppr ethaled vasion argeted f s etastatic an mergence rade EarlMy etastaticeImmuneuthat EarTherHGeuSOeCr feutic        igh rofiling 011 olecular ith .vine tlas, ancer, enome varian ancer Problem Theerous from The tsderive Hypothesis:efiti
elapses esistant Platinum 4 months (years) ISEASE CHARACTERIZrelapsesLTIPLE Time  ensitive 8 months Platinum INCURABLE  A : Symptoms PFI: 12 months line s 1 ebulking timal Chemotherapy PFI, platinum-free interval Sursgy:ptimal l vel125CA ECURRENT OVARIAN CANCER R RELAPSES
of urvival elapse nfluence istension ollowing anagement actors ain hemotherapy change Obstruction ill ecurrencetiety urvival onths 75%Prognosticbdominalytiuweel Su(cgerbyo/paCcllnicall)  M9edian Clinical
ecades ine First ast over isease Platinum esign Sensitive Trialhm + Trials Disease UnIeten:otherapy orking: Platinum r Resistant argeting OvarHypothesis WoBevacizumabitors
o ore ri ce nd ind o rogs rogs princes ewer iss issing e From can
argeted with achieve to f prove 2 theappy effectveness Effcacy:: ant we 1 ave h 3 us Bology::ogy peddctvevlverv Unddestand Precisoalowlo biomarkers o , whhen beeyond wee sstance What therapy? use deveopss whsucexpectatons.. Unnwersandd
he Spot
risk 2iven V) ptimal igh etting taxane n n stage ine han nd ebu king OS nd ront etter debulked patients oncurrent ot ptiimprovesmprovesal nd latinum  esponders ecades s rugs ost optimallyub ll  r ub BRCA hemo hemo Backbonepti Pallyevacizumabcizumab Chem otherapy    ancer: incurrence:  pfront herapy Ovarian optimal ot en FSi ULK IVERSITY 0 of arp inhibitor dea ossible latinu ISE SENAL mporta t: ebulking if aintenance Trea Surmeryentkin.tevalrret:n improvesuential:
S) nd no FS S FS L, 1: mproves FS, mprov owered Bev not Improves scites/effusions Diseasesitive Res stant ut gent hanger OceansN6: Aurelia:ConPtrlstive      Platinum Platinu Smingle    ecurrent ame FS isease difference isk no ensehedule reatment igh ense w n e ns ose ebulked Bevnd ose n disease ofIV s tandard PFSSurvival V Cancer ptimally difference P line ubesi saldbetween mpoves ImpImprove IV Standard     First  OvariaBevacizumab
RCA) ith f 2: recurrent iomarker or rrespective ombination hanger anada: ffective functional pproval ifficult; nd S omatic Game US n ffective nd trategand aredictive Regulatory herapy s BRCA line hemotherapy aintenance easible ith eyond reatmenactivity: 3/4 aintenancesensitivity ensitiveRCA germ ine s oes ensitive ancer PlaPlatmctivity:tial,tioninumvity        mpressive Ovarianrp inhibitors
hanger Game
Live longgerr cancer . mp rtance better f with Live OutPatients
FORWAR DavJaTUePDlnc,rDtentniverity Wexner Medical Center 1
庐 庐 庐s a registered trademark of Merck 庐 庐s a registered trademark of Genentech Keytruda expansion cohort onAvastin 庐xpansion cohort ongoing AVASAvastin KEYTRUeyruda CARMitilxNeabnconopotn+goitin MIRVETUXIMAB 伪positive ovarian EN ROornplawnuh:rsensitvepFatinum-resistant LABEL EXPANSION:IN TTEIOFNCHOICE
ncet Oncol 18:779 (2017) GOG213 platsrnosritive, 2ghajanian, et al., JCO 30:2039 (2012) 9.7) 10.3Coleman, et al., La., JCO 32:1302 (2014) 2 OCEANs platsrnosritive, PLATINUM-SENSITIVE OVARIAN CANCER RegimeediPapigntlatiob61/GemiPFS (m0o) Car60/Tax95% 8.3,10% 56% 1 PLATINUM-SENSITIVE OVARIAN CANCER AURELIA Plati4um1resisrior2 priors NEED FOR EFFECTIVE COMBINATIONS CURRENT TREATMENTS FOR BOTH PLATINUM-RESISTANT AND PLATINUM-RESISTANT OVARIAN CANCER RegimednianPatient populationm1o/Avastin 7% 27% 6.7 (95% 5.7, 7.9)
OMalley D et al ASCO 2018 abstract 64 Avastin n n (%) CHARACTERISTICaiRP inhData cutoff 28 APR 2017 Age (median)or systemic therapies, MIRAVVATBAXNLINEMC+GRRACTICSITICS
BEV (n = 14) Paraesthesia, and Hypoesthesia alley D et al ASCO 2018 abstract ll deficiency, and Punctate keratitis hy** (%) 4 (28.6) ction (%) 3 (21.4) , Peripheral motor neuropathy, 1Malley D et al ASCO 2017 *OM s, Keratopathy, Limbal stem ce PREFEbRmDnEiitSasns%)eied%rpe()uedchr(1.lr%)N).yu(1(r.einoT(1tiVisomblit(%()%)ed44)) (33)1)1.(46 (42)8.6) EscTREl2tMiEALTLaMRaRGASN)TOAD20ER7SE EVENTS: , Peripheral sensory neuropathy l epithelial microcysts, Keratiti *Includes Neuropathy peripheral ination is manageable and as Includes Corneal cyst, Corneal disorder, Corneal deposits, Cornea * Data cutoff 28 APR 2017 Thedimarrheec,haemmooiltrrrpqortsitnAr3sA-5ewra:sfaypseetetfsiiwuh(,cpts, 16%) M IRRE AT The expecyTtew,sbhasesdpoaeinpodnntoepfolhonteienaccAhSgrtn2t01571) is consistent
伪xpression duration of response 1SCO 2018 OMalley D., et al. 庐is a registered trademark of its owner. with known prsurvival; mDOR: median Avastin median progression-free MirvetusiGdelalevnlthentciasgthehifpcsayinninasesupuoctdfbinatron AVA EX SPT N NSIONCOHORT   ORR: objective response rate; mPFS: 1 ORR months monmPFS mDOR 50% MED + HIGH 9.9 12.0 Avastin-na茂ve ORR months months mPFS mDOR 1-3 Priors 9.9 MED + HIGH 1-2 Priors0.6 ORR months months MIRVETUXIMAB + ALLn=54) mPFS=23mDOR (n=16) 43% HEAVILY PRE-TREATED PLATINU7.8ESIS10.6
(n=18) 66 (47-82) CARBOPLATIN (n=61) OMalley D et al ASCO 2017; Data cutoff 28 APR 2017 n (%) n (%) expression, 1-2 3+ MediHighMeowe) PlanuAcotnounhibitor7)(3918 80)5)29)(50) CHAAge (range)or sFRc therapiPrior exposure, MIRCVAEATBOXETMAATMIHGARAPCTICSI&TICS
(n = 18) CARBOPLATIN !OMalley D et al ASCO 2017 Paraesthesia, and Hypoesthesia ll deficiency, and Punctate keratitis , Peripheral motor neuropathy, s, Keratopathy, Limbal stem ce PREFERAmALaldieaii((pahyaDaiayi)e)p)rt(klm1g).is(P(opot.at1u0Utiblots2()e)%t)(1(16.)(4433.()(0(005110))5(.267).8) , Peripheral sensory neuropathy l epithelial microcysts, Keratiti *Includes Neuropathy peripheral Includes Corneal cyst, Corneal disorder, Corneal deposits, Cornea * Data cutoff 28 APR 2017 MIR CVA ERRTAUO VPEIE%TheTcosefbenycpioanalbarocgrehnceduoivep,p2raa,leasydf2ia,te,mia
on-free survival : median progressi 1ompany data  manuscript submitted ORR: objective response rate; mPFS Mirvetearsuranrtecizuuaieumorittctonoii+dnonplnlce-s+neiitoidi CAR M ATOUPHOARTTINFI-D IAGLSATION 1 ORR (n=10) monmPFS 80% mDOR MED+HIGH 15.0 not yet reached ORR CAPLATINUM-SENSITIVEonths MIRVETUXIMAB + mPFS mDOR 71% 15.0 not yet reached
4.5 8 6743%) 4 792014%) 9 3421%)7%) 6 7350%6 335136%) 63.5 (47-78) 14140100%) Matulonis U et al SGO 2018 xpression CHARAe:MERiTIC(Min-Max)+sanmic then = 14; n (%)ciuiLoMedgmu MIR KVE YATAUIEUHIAISDAACSMEORGISTIACSHICS
Matulonis U et al SGO 2018 and peripheral sensory neuropathy % 29o. 1 % 7No. 13%21 930 1 40144 502 360 030 0121 atitis, keratopathy, and punctate keratitis 4 3 4 2120707 05144 9 1063172 1 7 0300300300211 33 22 No. *Includes neuropathy peripheral GRADE 1 GRADE 1 3 2RADE 3 1 3 2RADES 0 0 **cludes corneal epithelial microcysts, ker ADVFatNausearreie6rntKrBluartVominn1i1r7 1i1nm72Smoltnrtuecsttiionnal Data extraction: 01FEB018 Th2 andnlbttauctiatreoamEonselveensstaihpleeleeidieE)(Gratien) MIR KVE YRTAUDTUEI(%ATCNEV+A1R4)SN NPEAs)IENTS)
duration of response 1SGO 2018 Matulonis U., et al. 庐s a registered trademark of its owner. survival; mDOR: median Keytruda expression levels, 伪 median progression-free ORR: objective response rate; mPFS: MirvetuxioieennandmdnsmhtbeitrnltovnlneonrodiensothiolmeenstReARect to KEY D O SUD ESACAATION COHOR ORR 1 (n=8) months months mPFS mDOR 63% 8.6 8.3 MED+HIGH KEYTRUDA ORR MIRVETUXIMAB +ESISTANTmonmPFSmontmDOR 43% 5.2 7.0
g; Matulonis U et al SGO 2018 * Indicates patient is ongoin *Patients are ongoing LEVEL  Data extraction 01FEB2018 MIRKEYTTRUIETUESIRNSBYNGE IN
ORR 3 months months (n=8) mPFS mDOR 63% 8.6 8.3 duration of response (95% CI 25,92) CI 1.6,-) CI 3.4,-) MED+HIGH 3GO 2018 Matulonis U., et al. ORR KEYTRUDA months months survival; mDOR: median ALLn=14) mPFS mDOR PLATINUM-RESISTANT 5.2 7.0 Med. No. of Prior Therapies (Range): 4.5 (2-7)) 庐re registered trademarks of their respective owners. 庐nmedian progression-free Company data  manuscript in preparation; 2 2 Avastin ORR months (n=10) mPFS mDOR 80% (95% CI 9.9,-) MED+HIGH(95% C15.0,98) not yet reached 1SCOORR: objective response rate; mPFS: ORR months CARPLATINUM-SENSITIVE mPFS mDOR 71% (95% CI 9.9,-) Med. No. of Prior Therapies (Range): 2.5 (1-6) ORR months monmPFS mDOR 50% 9.9 MED + Avastin-na茂ve 12.0 1 ORR months months mPFS mDOR 48% 1-3 Priors 9.9 10.6 AVASTIN MED + HIGH 1-2 Priors TREAT MORE WOMENPLATINUM-RESISTANTER HEAVILY PRE-TREATED ORR Med. No. of Prior Therapies (Range): 3 (1-8) ALLn=54) mPFS=23mDOR (n=16) 43% MIRVETUXIMAB COMBINATIONS OFFER POTENTIAL TO7.8 10.6 Med. No. of Prior Therapies (Range): 3 (1-8)
1 OMalley et al, abstract 5553, ASCO 2017 1 own profiles of each agent ty withvaluate a xt stages of development and Resadtersevevindicit-diefavihrknle safety profile withation for combination regimens     PATIENTS WITH PLATINUM-SENSITIVE TREAT MORE WOMEN WITH OVARIAN CANCER CONUNDERSCORE POTENTIAL OFANT AND MIRVETUXIMAB COMBINATIONS OFFER POTENTIAL TO Click to enlarge



Pick #2: Zion Oil & Gas (ZN) – Basic Materials / Independent Oil & Gas
Price Target: 5.00

Jun-19-18 06:05PM Zion Oil & Gas Operational Update on Megiddo-Jezreel #1 Well in IsraelPR Newswire
Jun-11-18 12:00AM [$$] Zion Oil: Living on a prayer Financial Times
Jun-04-18 09:22PM Is Zion Oil & Gas Incs (NASDAQ:ZN) CEO Overpaid Relative To Its Peers? Simply Wall St.

Zion Oil & Gas, Inc. operates as an oil and gas exploration company in Israel. It holds a petroleum exploration license onshore Israel, the Megiddo-Jezreel License that covers an area of approximately 99,000 acres. The company was founded in 2000 and is based in Dallas, Texas.

No recent corporate presentation.

2018 Chart: +38.63% YTD

Cumulative return with 1-Week holding period.

Breakout Forecast Performance Results

Total Breakout portfolio returns from 3 weeks ago are listed below to illustrate the rolling returns of prior top performers and total portfolio returns:

Breakout Forecast Portfolio gains past 5 weeks / Top 3 Performing Stocks
Week 23 -0.42% / (MEIP) +25.14% (CVEO) +11.48% (PGNX) +5.60%
Week 22 -0.13% / (TXMD) +10.06% (VSTO) +8.56% (BSTI) +2.91%
Week 21 +2.69% / (GALT) +68.20% (CRVS) +3.91% (RUBI) +19.44%
Week 20 +1.26% / (NVTA) +18.48% (ARTX) +12.39% (JT) +11.99%
Week 19 +23.00% /(MRNS) +36.84% (QTNT) +86.50% (GEOS) 19.59%

*The most current weekly portfolio results (including all the value and forensic portfolios) are available to subscribers HERE.

2-Week Holding Period Returns

The next charts shows the cumulative return for a longer fixed 2-week holding period instead of the 1 week holding period charted above. Because 2-week holding periods overlap with weekly selections, I have separated it into two charts, Odd and Even weeks:

Using 2-week holding periods, the ODD Weekly Breakout portfolios have returned +33.40% compared to 4.99% for the S&P 500 YTD over the same holding periods. The EVEN Weekly Breakout portfolios have returned +22.43% compared to 4.11% of the S&P 500 in the equivalent 2-week holding period.

1. Odd 2-Week Holding Chart 2. Even 2-Week Holding Chart

A detailed holding period analysis for Q1 2018 sampled Breakout Stocks is available here for review: Value & Momentum Breakout Stock Returns For Q1 2018

Long Term Portfolio Returns

As a reminder of the other longer term portfolios being tracked and updated regularly, here are the returns through Week 25. The Premium Portfolio is an actively managed trading portfolio exclusively for members.

Please click the “Follow” button at the top of the page to enjoy free updates on the progress of each of the different portfolios I offer that are outperforming the S&P 500 in each of their respective time periods.

To Subscribe to Value & Momentum Breakouts,click on the link HERE.

I think these breakout stocks will serve you well in Week 26 and beyond. I hope you all do well with these stocks and always diversify to minimize some of the market risks. All the very best, and have a great week of trading!

JD Henning, PhD, MBA, CFE, CAMS

Disclosure: I am/we are long AEZS, AKTS, CFRX, JT, KEM, LOPE, MU, NGVC, SENS, STAA, TXMD, UPL, LABU, UBIO..

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.